FDA Approvals, News & UpdatesKidney CancerNewsworthy

Opdivo plus Yervoy First Immunotherapy Regimen for Initial Treatment of Kidney Cancer

The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer.
October 2018 Vol 4 No 5 – October 17, 2018

In April 2018, the FDA approved the use of 2 immunotherapies—Opdivo and Yervoy (nivolumab and ipilimumab; from Bristol-Myers Squibb)—for the treatment of patients with intermediate-risk or poor-risk advanced renal-cell carcinoma, or kidney cancer. This is the first immunotherapy regimen approved by the FDA for patients with kidney cancer. The majority of patients (about 75%) with advanced kidney cancer have disease that is considered at risk.

The FDA has previously approved this immunotherapy combination for use in patients with advanced melanoma and for patients with colorectal cancer. This new approval for kidney cancer was based on results from the clinical trial called CheckMate-214 that included 847 patients with intermediate-risk or poor-risk advanced kidney cancer who had not received any therapy before.

The use of the 2 immunotherapies led to improved outcomes in about 42% of patients compared with only about 27% of patients who received the targeted drug Sutent (sunitinib), which was previously approved for advanced kidney cancer.

The main side effects reported with nivolumab and ipilimumab in this study were fatigue, rash, diarrhea, musculoskeletal pain, nausea, cough, fever, joint inflammation, and decreased appetite.

Recommended For You
FDA Approvals, News & UpdatesLeukemia
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Breast CancerFDA Approvals, News & Updates
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
Bladder CancerFDA Approvals, News & Updates
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Last modified: December 12, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.